Global Antisense & RNAi Therapeutics Market Overview:
Global Antisense & RNAi Therapeutics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Antisense & RNAi Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Antisense & RNAi Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Antisense & RNAi Therapeutics Market:
The Antisense & RNAi Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Antisense & RNAi Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Antisense & RNAi Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Antisense & RNAi Therapeutics market has been segmented into:
RNA Interference and RNA Antisense
By Application, Antisense & RNAi Therapeutics market has been segmented into:
Intravenous Route
Subcutaneous Route
Intrathecal Route
Pulmonary Delivery
Intraperitoneal Injection
and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antisense & RNAi Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antisense & RNAi Therapeutics market.
Top Key Players Covered in Antisense & RNAi Therapeutics market are:
Alnylam Pharmaceuticals
Inc.
Biogen Inc.
Ionis Pharmaceuticals (Akcea Therapeutics
Inc.)
Sarepta Therapeutics
Inc.
Novartis AG
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Antisense & RNAi Therapeutics Market Type
4.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
4.2 Antisense & RNAi Therapeutics Market Overview
4.3 RNA Interference and RNA Antisense
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 RNA Interference and RNA Antisense: Geographic Segmentation Analysis
Chapter 5: Antisense & RNAi Therapeutics Market Application
5.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
5.2 Antisense & RNAi Therapeutics Market Overview
5.3 Intravenous Route
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Intravenous Route: Geographic Segmentation Analysis
5.4 Subcutaneous Route
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Subcutaneous Route: Geographic Segmentation Analysis
5.5 Intrathecal Route
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Intrathecal Route: Geographic Segmentation Analysis
5.6 Pulmonary Delivery
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Pulmonary Delivery: Geographic Segmentation Analysis
5.7 Intraperitoneal Injection
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Intraperitoneal Injection: Geographic Segmentation Analysis
5.8 and Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Antisense & RNAi Therapeutics Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ALNYLAM PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.
6.4 BIOGEN INC.
6.5 IONIS PHARMACEUTICALS (AKCEA THERAPEUTICS
6.6 INC.)
6.7 SAREPTA THERAPEUTICS
6.8 INC.
6.9 NOVARTIS AG
Chapter 7: Global Antisense & RNAi Therapeutics Market By Region
7.1 Overview
7.2. North America Antisense & RNAi Therapeutics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 RNA Interference and RNA Antisense
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Intravenous Route
7.2.3.2 Subcutaneous Route
7.2.3.3 Intrathecal Route
7.2.3.4 Pulmonary Delivery
7.2.3.5 Intraperitoneal Injection
7.2.3.6 and Others
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Antisense & RNAi Therapeutics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 RNA Interference and RNA Antisense
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Intravenous Route
7.3.3.2 Subcutaneous Route
7.3.3.3 Intrathecal Route
7.3.3.4 Pulmonary Delivery
7.3.3.5 Intraperitoneal Injection
7.3.3.6 and Others
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Antisense & RNAi Therapeutics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 RNA Interference and RNA Antisense
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Intravenous Route
7.4.3.2 Subcutaneous Route
7.4.3.3 Intrathecal Route
7.4.3.4 Pulmonary Delivery
7.4.3.5 Intraperitoneal Injection
7.4.3.6 and Others
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Antisense & RNAi Therapeutics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 RNA Interference and RNA Antisense
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Intravenous Route
7.5.3.2 Subcutaneous Route
7.5.3.3 Intrathecal Route
7.5.3.4 Pulmonary Delivery
7.5.3.5 Intraperitoneal Injection
7.5.3.6 and Others
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Antisense & RNAi Therapeutics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 RNA Interference and RNA Antisense
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Intravenous Route
7.6.3.2 Subcutaneous Route
7.6.3.3 Intrathecal Route
7.6.3.4 Pulmonary Delivery
7.6.3.5 Intraperitoneal Injection
7.6.3.6 and Others
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Antisense & RNAi Therapeutics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 RNA Interference and RNA Antisense
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Intravenous Route
7.7.3.2 Subcutaneous Route
7.7.3.3 Intrathecal Route
7.7.3.4 Pulmonary Delivery
7.7.3.5 Intraperitoneal Injection
7.7.3.6 and Others
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Antisense & RNAi Therapeutics Scope:
|
Report Data
|
Antisense & RNAi Therapeutics Market
|
|
Antisense & RNAi Therapeutics Market Size in 2025
|
USD XX million
|
|
Antisense & RNAi Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Antisense & RNAi Therapeutics Base Year
|
2024
|
|
Antisense & RNAi Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Alnylam Pharmaceuticals, Inc., Biogen Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Sarepta Therapeutics, Inc., Novartis AG.
|
|
Key Segments
|
By Type
RNA Interference and RNA Antisense
By Applications
Intravenous Route
Subcutaneous Route
Intrathecal Route
Pulmonary Delivery
Intraperitoneal Injection
and Others
|
